Drug discovery

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not looking so rosy for Janssen’s HIV vaccine […]

This is an extraordinarily exciting time to be involved in precision medicine for cancer. This new whitepaper reviews some of the topics and trends in this emerging research area, including: 3D cultures: Spheroids and organoids Organoids in cancer research Tumour microenvironments Organ-on-a-chip and body-on-a-chip 3D bioprinting

Collaborative working between the NHS and industry could reduce variations in uptake of innovative treatments across the UK, a joint report from NHS Confederation and ABPI argues.   Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments in these […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with two experts when it comes to clinical trials. First up is Livia Ng, […]

1. Antonin (Tony) de Fougerolles, Etherna  Antonin (Tony) de Fougerolles has joined the Etherna board of directors as an independent member.  He is currently the CEO of Evox Therapeutics. As founding Chief Scientific Officer (CSO) at Moderna Therapeutics, he pioneered modified mRNA.  2. Dr Xavier Jacq, Ubiquigent Ubiquigent has appointed Dr Xavier Jacq to its […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Once again, research partnerships and licence agreements have dominated the news this week, as drug discovery companies seek new ways to combine their […]

News round-up for 9-13 January by DDW Digital Content Editor Diana Spencer. Once again, research partnerships and licence agreements have dominated the news this week, as drug discovery companies seek new ways to combine their expertise to address unmet medical needs.  The top stories:  Alliance to develop circular RNA-based therapeutics  Esperovax and Ginkgo Bioworks have agreed […]

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. This license allows us to […]

X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline.   Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.  […]

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations […]